News | Latest Breaking News Stories & Headlines

AstraZeneca moves to direct US listing, keeps UK listing

AstraZeneca has laid out plans to directly list its shares in the US, as the drugmaker seeks to maximise gains from its biggest market and investor pool, even as it said that it was not exiting London.

Business • 2 hrs

AstraZeneca beats second-quarter profit expectations

AstraZeneca has today beaten second-quarter profit forecastson robust sales of cancer, heart and kidney disease drugs and strong demand in the US, where it has invested $50 billion to expand amid tariff threats from President Donald Trump.

Business • 29 Jul

AstraZeneca's $50 billion US investment as tarrifs loom

AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the US by 2030, it said, the latest big investment by a pharmaceutical company reacting to President Donald Trump's tariff policy.

Business • 22 Jul

AstraZeneca facing a fine of up to $8m over suspected unpaid import taxes in China

AstraZeneca may face further import tax fine from China

AstraZeneca said today it may face a fine of up to $8m over suspected unpaid import taxes in China as the drugmaker works to boost business in its second-biggest market after scandals including the arrest of its China president last year.

Business • 29 Apr

AstraZeneca said its 2025 revenue was expected to increase by a high single-digit percentage

AstraZeneca shares rise as China probe update reassures

AstraZeneca shares rose today after the drugmaker said it could face a fine of up to $4.5m in China over suspected unpaid import taxes for two cancer drugs, reassuring analysts and investors that the business impact would be minor.

Business • 06 Feb

British finance minister Rachel Reeves wants to reduce state provisions to the vaccine centre

AstraZeneca threatens to move UK vaccine production to US

AstraZeneca has warned it could relocate its vaccine manufacturing site from the UK to the US amid a deadlock with the new UK Labour government over plans to cut state aid, the Financial Times reported.

Business • 23 Aug 24

AstraZeneca has been expanding into markets like China, Indonesia and India over the past few years in an effort to widen its supply chain

AstraZeneca's $1.5bn cancer drug plant for Singapore

AstraZeneca plans to build a $1.5 billion manufacturing facility in Singapore to produce a promising category of cancer-killing drugs called antibody-drug conjugates (ADCs), the Anglo-Swedish drugmaker said today.

Business • 20 May 24

The company said it would proceed to withdraw the vaccine Vaxzevria's marketing authorisations within Europe

AstraZeneca withdraws Covid jab 'for commercial reasons'

Anglo-Swedish pharmaceutical company AstraZeneca has said it was withdrawing its Covid-19 vaccine Vaxzevria, one of the first produced in the deadly pandemic, citing "commercial reasons" following a slump in demand.

Coronavirus • 08 May 24

AstraZeneca is buying clinical-stage biopharmaceutical company Fusion Pharmaceuticals for about $2 billion in cash

AstraZeneca eyes new cancer treatments with Fusion deal

AstraZeneca said today it will buy clinical-stage biopharmaceutical company Fusion Pharmaceuticals for about $2 billion in cash as the Anglo-Swedish drugmaker bets on next-generation cancer treatments.

Business • 19 Mar 24

AstraZeneca said the acquisition would help to boost its rare disease division, Alexion

AstraZeneca to acquire Amolyt Pharma for $1bn

AstraZeneca is to acquire Amolyt Pharma in a deal potentially worth more than $1 billion.

Business • 14 Mar 24

AstraZeneca moved into the fast-paced respiratory syncytial virus (RSV) vaccines and the obesity drugs race through several deals last year

Drugmaker AstraZeneca targets 2024 growth

AstraZeneca expects to boost 2024 revenue and profit on the back of its blockbuster cancer drugs, but lower than expected fourth-quarter profit dragged the London-listed drugmaker's shares down more than 5% today.

Business • 08 Feb 24

AstraZeneca said that in the first nine months of this year, nine medicines delivered more than $1 billion in revenue

AstraZeneca ups profit outlook on cancer drugs demand

AstraZeneca has today raised its annual earnings forecast, helped by strong demand for its cancer drugs, and reported third-quarter profit and revenue just ahead of analyst expectations even as Covid-19 vaccine sales evaporated.

Business • 09 Nov 23

AstraZeneca shares closed down 3.2% after earlier touching their lowest since July 19.

AstraZeneca seeks to calm CEO speculation

AstraZeneca appeared to play down speculation about the future of its CEO after its shares fell more than 4% today following a British tabloid report that Pascal Soriot was considering leaving the drugmaker as soon as next year.

Business • 11 Sep 23

Albert Manifold, the CEO of building materials giant, got paid £10.38m last year

CRH CEO Manifold third best paid boss at FTSE company

The bosses of the biggest listed companies on the London FTSE index saw their pay surge by 16% last year as most workers saw their pay packets outstripped by inflation, according to new research.

Business • 22 Aug 23

AstraZeneca has secured approval for a $360m active pharma ingredient (API) manufacturing facility for north Dublin

Green light for AstraZeneca's $360m API plant in Dublin

Covid-19 vaccine maker AstraZeneca has secured the green light for a $360m "next generation" active pharma ingredient (API) manufacturing facility for north Dublin.

Business • 08 May 23

New accounts for the Dublin based Alexion Pharma International Operations Ltd (APIO) show that it recorded pre-tax losses of $101.42 million in 2021

Pay to directors at AstraZeneca Dublin unit hits €12m

Pay to directors at the main Irish subsidiary of Covid-19 vaccine maker, AstraZeneca increased four fold to €12 million or $12.98 million in 2021.

Business • 09 Feb 23

AstraZeneca CEO Pascal Soriot said the firm was on a path to deliver at least 15 new medicines this decade

AstraZeneca goes for growth with new drugs

AstraZeneca has today forecast growth in 2023 earnings and revenue as the British drugmaker seeks to offset declining sales of Covid-19 medicines with its cancer, metabolic and rare disease drugs.

Business • 09 Feb 23

AstraZeneca has lodged plans for a $360m "next generation" active pharma ingredient (API) manufacturing facility for Dublin

AstraZeneca's $360m plan for 'next generation' plant

Covid-19 vaccine maker AstraZeneca has lodged plans for a $360m "next generation" active pharma ingredient (API) manufacturing facility for north Dublin.

Business • 07 Feb 23

Core to the deal is CinCor's experimental therapy baxdrostat

AstraZeneca to buy drug developer CinCor Pharma

AstraZeneca has said it has struck a deal to buy US-based drug developer CinCor Pharma for up to $1.8 billion to increase its stock of heart and kidney drugs.

Business • 09 Jan 23

Sales of AstraZeneca's key cancer medicines - Tagrisso and Imfinzi - helped the company's revenue beat

AstraZeneca tops estimates buoyed by cancer drug sales

AstraZeneca has today topped analysts' expectations for third-quarter profit and revenue, helped by sales of its key cancer drugs, and raised its full-year adjusted earnings forecast.

Business • 10 Nov 22

Ireland is becoming an increasingly critical global hub for AstraZeneca operations, the company has said

AstraZeneca's Alexion to invest €65m in Irish operation

AstraZeneca's Rare Disease group, Alexion, is investing €65m in new and enhanced capabilities across its sites in College Park in Blanchardstown and Monksland Industrial Park in Athlone.

Business • 24 Jun 22

AstraZeneca said sales of Covid-19 products were expected to decline by a low-to-mid 20s percentage this year

AstraZeneca sees higher 2022 sales but Covid boost dips

AstraZeneca has forecast higher 2022 sales and raised its annual dividend for the first time in a decade after beating fourth-quarter profit expectations, but warned the boost from its Covid-19 products would fall.

Business • 10 Feb 22

AstraZeneca reports $1.05 billion in Covid-19 vaccine sales for the third quarter

AstraZeneca makes over $1 billion in Q3 vaccine sales

AstraZeneca has today posted $1.05 billion in Covid-19 vaccine sales for the third quarter and the not-for-profit vaccine added one cent to profit in the period.

Business • 12 Nov 21

The $360m planned investment at the Alexion Campus in College Park in Blanchardstown is expected to create about 100 highly skilled direct jobs, including scientists and engineers.

AstraZeneca to create 100 jobs in new Dublin plant

Biopharmaceutical company AstraZeneca is planning to set up a next-generation active pharmaceutical ingredient (API) manufacturing facility in Dublin to ensure its global supply network is fit for future growth.

Business • 21 Sep 21

The EMA recommended that a warning be added to information on the vaccine

Nerve disorder listed as 'rare' side effect of AZ jab

The European Medicines Agency has listed the neurological disorder Guillain-Barre syndrome, which can cause temporary paralysis, as a "very rare" side effect of the AstraZeneca Covid-19 vaccine.

Coronavirus • 09 Sep 21

Astrazeneca